NASDAQ:AMED Amedisys (AMED) Stock Price, News & Analysis $94.50 +0.23 (+0.24%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$94.46 -0.04 (-0.04%) As of 04/25/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Amedisys Stock (NASDAQ:AMED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amedisys alerts:Sign Up Key Stats Today's Range$94.00▼$94.8850-Day Range$90.43▼$94.5052-Week Range$82.15▼$98.95Volume361,426 shsAverage Volume404,999 shsMarket Capitalization$3.10 billionP/E Ratio37.50Dividend YieldN/APrice Target$100.75Consensus RatingHold Company OverviewAmedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More… Amedisys Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreAMED MarketRank™: Amedisys scored higher than 55% of companies evaluated by MarketBeat, and ranked 218th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmedisys has only been the subject of 2 research reports in the past 90 days.Read more about Amedisys' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth10.00% Earnings GrowthEarnings for Amedisys are expected to grow by 10.00% in the coming year, from $4.40 to $4.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 37.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 37.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.43.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 1.78. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.26% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Amedisys has recently decreased by 1.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Sustainability and ESG5.0 / 5Environmental Score-0.61 Percentage of Shares Shorted7.26% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Amedisys has recently decreased by 1.69%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.92 News SentimentAmedisys has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Amedisys this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for AMED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amedisys is held by insiders.Percentage Held by Institutions94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amedisys' insider trading history. Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Stock News HeadlinesEquities Analysts Offer Predictions for Amedisys Q2 EarningsApril 27 at 2:03 AM | americanbankingnews.comAmedisys, Inc.: Amedisys Reports First Quarter 2025 Financial ResultsApril 25 at 1:43 AM | finanznachrichten.deFrom Social Security to Social Prosperity?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 28, 2025 | Paradigm Press (Ad)Amedisys reports Q1 adjusted EPS $1.25, consensus $1.11April 25 at 1:43 AM | markets.businessinsider.comWilliam Blair Sticks to Its Hold Rating for Amedisys (AMED)April 25 at 1:43 AM | markets.businessinsider.comAmedisys Inc (AMED) Reports Strong Q1 2025 Financial Results Amid Pending Merger | AMED stock newsApril 23, 2025 | gurufocus.comAmedisys Inc Q1 2025 Earnings: EPS of $1.84 Beats Estimates, Revenue Slightly Misses at $594. ...April 23, 2025 | gurufocus.comAmedisys Extends Credit Facility Amid Merger TalksApril 23, 2025 | tipranks.comSee More Headlines AMED Stock Analysis - Frequently Asked Questions How have AMED shares performed this year? Amedisys' stock was trading at $90.79 on January 1st, 2025. Since then, AMED shares have increased by 4.1% and is now trading at $94.50. View the best growth stocks for 2025 here. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Wednesday, April, 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The health services provider had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a trailing twelve-month return on equity of 12.20% and a net margin of 3.57%. Who are Amedisys' major shareholders? Amedisys' top institutional investors include SG Americas Securities LLC (0.17%), Bridge City Capital LLC (0.11%), New York State Teachers Retirement System (0.08%) and Amalgamated Bank (0.05%). Insiders that own company stock include Denise M Bohnert and Michael Paul North. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings4/23/2025Today4/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNASDAQ:AMED CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees20,000Year Founded1982Price Target and Rating Average Stock Price Target$100.75 High Stock Price Target$101.00 Low Stock Price Target$100.00 Potential Upside/Downside+6.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$2.71 Trailing P/E Ratio37.50 Forward P/E Ratio21.48 P/E Growth1.78Net Income$-9,750,000.00 Net Margins3.57% Pretax Margin5.80% Return on Equity12.20% Return on Assets6.74% Debt Debt-to-Equity Ratio0.05 Current Ratio1.19 Quick Ratio1.19 Sales & Book Value Annual Sales$2.37 billion Price / Sales1.31 Cash Flow$6.39 per share Price / Cash Flow14.80 Book Value$34.31 per share Price / Book2.75Miscellaneous Outstanding Shares32,810,000Free Float32,066,000Market Cap$3.10 billion OptionableOptionable Beta0.89 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:AMED) was last updated on 4/28/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedisys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.